1. Home
  2. NXJ vs TRDA Comparison

NXJ vs TRDA Comparison

Compare NXJ & TRDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Nuveen New Jersey Qualified Municipal Fund

NXJ

Nuveen New Jersey Qualified Municipal Fund

HOLD

Current Price

$12.41

Market Cap

503.5M

Sector

Finance

ML Signal

HOLD

TRDA

Entrada Therapeutics Inc.

HOLD

Current Price

$6.79

Market Cap

500.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NXJ
TRDA
Founded
1999
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
503.5M
500.4M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
NXJ
TRDA
Price
$12.41
$6.79
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$21.00
AVG Volume (30 Days)
95.2K
356.4K
Earning Date
01-01-0001
05-08-2026
Dividend Yield
3.27%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$25,421,000.00
Revenue This Year
N/A
$39.97
Revenue Next Year
N/A
$50.80
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.06
$4.93
52 Week High
$12.90
$16.45

Technical Indicators

Market Signals
Indicator
NXJ
TRDA
Relative Strength Index (RSI) 55.04 26.90
Support Level $11.94 $5.53
Resistance Level $12.76 $6.88
Average True Range (ATR) 0.09 1.02
MACD 0.01 -0.65
Stochastic Oscillator 69.38 9.89

Price Performance

Historical Comparison
NXJ
TRDA

About NXJ Nuveen New Jersey Qualified Municipal Fund

Nuveen New Jersey Quality Municipal Income Fund is a closed-end investment management company. Its objective is to provide current income exempt from regular federal and New Jersey income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued. The company invests a majority of its managed assets in securities rated, at the time of investment, investment grade or, if the bonds are unrated, are judged by the manager to be of comparable quality.

About TRDA Entrada Therapeutics Inc.

Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.

Share on Social Networks: